Adjuvance is building a pipeline of candidate vaccines using our adjuvants. We have progressed development of improved acellular pertussis and shingles vaccines that are designed to provide clinically-relevant improvement over current vaccines. Adjuvance may seek out-licensing partners to continue the development and commercialization of these vaccines.
Improved shingles vaccine
Shingles (also known as herpes zoster) is a painful rash that develops, often on the face or torso, and has the potential complication of pain that can last for months or even years. Vaccination against shingles is recommended in the United States and many countries for older adults and people with weak immune systems. Available shingles vaccines contain the saponin adjuvant QS-21 and the toll-like receptor (TLR) 4 agonist adjuvant monophosphoryl lipid A (MPL), known together as the AS01 adjuvant. The adjuvanted shingles vaccine is highly effective, but can cause short-term adverse events more intense than other vaccines. About 1 out of 6 people who got the available shingles vaccine experienced side effects that prevented them from doing regular activities. Symptoms went away on their own in about 2 to 3 days.
Our solution is to develop a vaccine with the same effectiveness and a better experience for vaccine recipients through using an Adjuvance combination adjuvant that includes TQL-1055 instead of QS-21. Pre-clinical data demonstrate the potential for TQL-1055 combined with a TLR4 agonist to provide an immune response similar to AS01.
Figure 1 Immune response in mice
Adjuvanted pertussis vaccine
Commonly known as whooping cough, pertussis is a respiratory illness that spreads from person to person. Vaccination against pertussis occurs throughout life and is recommended in many countries for all children and adults. Reported annual cases of pertussis in the United States have increased 10-fold between the 1970s and 2010s, revealing the need for more effective vaccines and vaccination. Our solution is to combine TQL-1055 with a pertussis vaccine to increase the immune response and vaccine effectiveness.
The Phase 1, randomized, double-blind, active-controlled, dose-escalation study to assess the safety and immunogenicity of Pertussis Acellular Vaccine Adjuvanted with TQL-1055 (PAVA) enrolled 72 healthy adults 18-50 years of age and evaluated six escalating dose levels of TQL-1055, co-administered with a TdaP vaccine. More details on the clinical trial can be found at clinicaltrials.gov under identifier NCT04793620.
Results from the PAVA trial presented during the 2021 IDWeek meeting are available under PRESENTATIONS.